PL3555107T3 - Sposób wytwarzania (S)-2-((2-((S)-4-(difluorometylo)-2-oksooksazolidyn-3-ylo)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oksazepin-9-ylo)amino)propanamidu - Google Patents
Sposób wytwarzania (S)-2-((2-((S)-4-(difluorometylo)-2-oksooksazolidyn-3-ylo)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oksazepin-9-ylo)amino)propanamiduInfo
- Publication number
- PL3555107T3 PL3555107T3 PL17835634T PL17835634T PL3555107T3 PL 3555107 T3 PL3555107 T3 PL 3555107T3 PL 17835634 T PL17835634 T PL 17835634T PL 17835634 T PL17835634 T PL 17835634T PL 3555107 T3 PL3555107 T3 PL 3555107T3
- Authority
- PL
- Poland
- Prior art keywords
- oxooxazolidin
- oxazepin
- dihydrobenzo
- propanamide
- imidazo
- Prior art date
Links
- SGEUNORSOZVTOL-CABZTGNLSA-N (2S)-2-[[2-[(4S)-4-(difluoromethyl)-2-oxo-1,3-oxazolidin-3-yl]-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]amino]propanamide Chemical compound FC([C@H]1N(C(OC1)=O)C=1N=C2N(CCOC3=C2C=CC(=C3)N[C@H](C(=O)N)C)C=1)F SGEUNORSOZVTOL-CABZTGNLSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662434836P | 2016-12-15 | 2016-12-15 | |
| EP17835634.1A EP3555107B1 (en) | 2016-12-15 | 2017-12-15 | Process for the preparation of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide |
| PCT/EP2017/083143 WO2018109204A1 (en) | 2016-12-15 | 2017-12-15 | Process for the preparation of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino) propanamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3555107T3 true PL3555107T3 (pl) | 2021-07-05 |
Family
ID=61027659
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20209166.6T PL3851441T3 (pl) | 2016-12-15 | 2017-12-15 | Proces otrzymywania (S)-2-((2-((S)-4-(difluorometylo)-2-oksooksazolidyn-3-ylo)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oksazepin-9-ylo)amino)propanamidu |
| PL17835634T PL3555107T3 (pl) | 2016-12-15 | 2017-12-15 | Sposób wytwarzania (S)-2-((2-((S)-4-(difluorometylo)-2-oksooksazolidyn-3-ylo)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oksazepin-9-ylo)amino)propanamidu |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20209166.6T PL3851441T3 (pl) | 2016-12-15 | 2017-12-15 | Proces otrzymywania (S)-2-((2-((S)-4-(difluorometylo)-2-oksooksazolidyn-3-ylo)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oksazepin-9-ylo)amino)propanamidu |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10781219B2 (pl) |
| EP (2) | EP3851441B1 (pl) |
| JP (1) | JP7004720B2 (pl) |
| KR (1) | KR102537048B1 (pl) |
| CN (1) | CN110088111B (pl) |
| AR (1) | AR110527A1 (pl) |
| AU (2) | AU2017378188B2 (pl) |
| ES (2) | ES2953833T3 (pl) |
| HR (2) | HRP20210592T1 (pl) |
| HU (1) | HUE062517T2 (pl) |
| IL (2) | IL267265B (pl) |
| MX (2) | MX377921B (pl) |
| PL (2) | PL3851441T3 (pl) |
| SG (1) | SG10201913961PA (pl) |
| SI (1) | SI3555107T1 (pl) |
| TW (1) | TWI770093B (pl) |
| WO (1) | WO2018109204A1 (pl) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111909173B (zh) | 2015-07-02 | 2025-03-04 | 豪夫迈·罗氏有限公司 | 苯并氧氮杂䓬噁唑烷酮化合物及其使用方法 |
| IL298518B2 (en) * | 2017-04-28 | 2025-05-01 | Hoffmann La Roche | Polymorphs and solid forms of (S)–2–((2–((S–4–(difluoromethyl)–2–oxoxazolidin-3–yl)–5,6–dihydrobenzo[F]imidazo[1,2–D][1,4]oxazepin-9–yl)amino)propanamide and methods of preparation |
| WO2021041348A1 (en) | 2019-08-26 | 2021-03-04 | Arvinas Operations, Inc. | Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders |
| CN113227101B (zh) * | 2019-11-25 | 2024-10-11 | 上海翰森生物医药科技有限公司 | 含三并环类衍生物的盐或晶型及其药物组合物 |
| CA3166087C (en) * | 2020-03-03 | 2025-05-13 | Momentive Performance Materials Inc. | CATALYST COMPOSITION |
| KR20240013791A (ko) * | 2021-05-28 | 2024-01-30 | 제넨테크, 인크. | 벤족사제핀 옥사졸리디논 화합물을 제조하기 위한 공정 |
| TW202440096A (zh) | 2023-03-24 | 2024-10-16 | 美商亞文納營運公司 | 雌激素受體降解劑之給藥方案 |
| TW202517655A (zh) * | 2023-07-14 | 2025-05-01 | 瑞士商赫孚孟拉羅股份公司 | 使用［Ｃｕ（μ－ｓａｌｂｅｎ）］錯合物之Ｃ－Ｎ偶合方法 |
| KR20260049827A (ko) | 2023-08-11 | 2026-04-14 | 에프. 호프만-라 로슈 아게 | 코팅 정제를 포함하는 약학적 제제 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI423980B (zh) | 2009-09-28 | 2014-01-21 | Hoffmann La Roche | 苯并氧氮呯ｐｉ３ｋ抑制劑化合物及使用方法 |
| KR20140032383A (ko) * | 2011-03-21 | 2014-03-14 | 에프. 호프만-라 로슈 아게 | Pi3k p110 델타에 대하여 선택적인 벤즈옥사제핀 화합물 및 이의 사용 방법 |
| US9303043B2 (en) | 2013-03-13 | 2016-04-05 | Greentech, Inc. | Process for making benzoxazepin compounds |
| CN111909173B (zh) * | 2015-07-02 | 2025-03-04 | 豪夫迈·罗氏有限公司 | 苯并氧氮杂䓬噁唑烷酮化合物及其使用方法 |
| IL298518B2 (en) | 2017-04-28 | 2025-05-01 | Hoffmann La Roche | Polymorphs and solid forms of (S)–2–((2–((S–4–(difluoromethyl)–2–oxoxazolidin-3–yl)–5,6–dihydrobenzo[F]imidazo[1,2–D][1,4]oxazepin-9–yl)amino)propanamide and methods of preparation |
-
2017
- 2017-12-15 PL PL20209166.6T patent/PL3851441T3/pl unknown
- 2017-12-15 AU AU2017378188A patent/AU2017378188B2/en active Active
- 2017-12-15 EP EP20209166.6A patent/EP3851441B1/en active Active
- 2017-12-15 JP JP2019531931A patent/JP7004720B2/ja active Active
- 2017-12-15 WO PCT/EP2017/083143 patent/WO2018109204A1/en not_active Ceased
- 2017-12-15 MX MX2019006958A patent/MX377921B/es unknown
- 2017-12-15 ES ES20209166T patent/ES2953833T3/es active Active
- 2017-12-15 CN CN201780078083.8A patent/CN110088111B/zh active Active
- 2017-12-15 PL PL17835634T patent/PL3555107T3/pl unknown
- 2017-12-15 HU HUE20209166A patent/HUE062517T2/hu unknown
- 2017-12-15 EP EP17835634.1A patent/EP3555107B1/en active Active
- 2017-12-15 ES ES17835634T patent/ES2867389T3/es active Active
- 2017-12-15 SI SI201730711T patent/SI3555107T1/sl unknown
- 2017-12-15 AR ARP170103528A patent/AR110527A1/es active IP Right Grant
- 2017-12-15 HR HRP20210592TT patent/HRP20210592T1/hr unknown
- 2017-12-15 HR HRP20230948TT patent/HRP20230948T1/hr unknown
- 2017-12-15 SG SG10201913961PA patent/SG10201913961PA/en unknown
- 2017-12-15 TW TW106144193A patent/TWI770093B/zh active
- 2017-12-15 KR KR1020197020323A patent/KR102537048B1/ko active Active
-
2019
- 2019-06-12 IL IL267265A patent/IL267265B/en active IP Right Grant
- 2019-06-13 MX MX2020010948A patent/MX2020010948A/es unknown
- 2019-06-14 US US16/441,765 patent/US10781219B2/en active Active
-
2021
- 2021-02-17 AU AU2021201046A patent/AU2021201046A1/en not_active Abandoned
- 2021-02-24 IL IL281087A patent/IL281087A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL281087A (en) | Process for preparing (S)-2-((2-((S)-4-(difluoromethyl)-2-oxoxazolidine-3-YL)-6,5-dihydrobenzo[F]imidazo[2,1-D][4 , 1]oxazapine-9-YL)amino)propanamide | |
| IL267464A (en) | Polymorphs and solid forms of (s)-2-((2-((s-4-(difluoromethyl)-2-oxoxolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][ 1,4]oxazepin-9-yl)amino)propanamide and methods of production | |
| IL266170A (en) | A process for the preparation of pyrazolo[1,5-a]pyrimidines and their salts | |
| IL288080A (en) | A process for the preparation of h7-pyrrolo[3,2-d]pyrimidine derivatives and their artificial intermediates | |
| IL276917A (en) | A process for the preparation of alubixivet | |
| SI3097098T1 (sl) | Postopek za pripravo N-((3-aminooksetana-3-il)metil)-2-(1,1-diokso- 3,5-dihidro-1,4-benzotiazepin-4-il)-6-metil-kinazolin-4-amina | |
| SG10202110927VA (en) | Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1h-imidazo[1,5-a]pyrazin-2-yl]-carboxylic acid | |
| PT3580219T (pt) | Processo para a preparação de remimazolam e formas de estado sólido de sais de remimazolam | |
| IL260999B (en) | A method for the preparation of a pyrrolo[3,2-d] pyrimidine compound, and its intermediates | |
| IL260465B (en) | A process for preparing an antibody-rifamycin conjugate | |
| HUE063118T2 (hu) | Eljárás N-alkil-nitrátoetilnitraminok elõállítására | |
| EP3405456A4 (en) | PROCESS FOR THE PREPARATION OF 4-ALKOXY-3-ACETOXYPICOLINIC ACIDS | |
| IL281254A (en) | A process for the preparation of lanbatinib | |
| IL248965A0 (en) | Polymorphs of 2-(4-(2-(1-isopropyl-3-methyl-1h-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d] [1,4]oxazapine-9-yl)-2-methylpropanamide, preparation methods and their pharmaceutical uses | |
| EP3422855A4 (en) | PROCESS FOR THE PREPARATION OF 4-ALKOXY-3-HYDROXYPICOLIC ACIDS | |
| EP3294703A4 (en) | A process for the preparation of verapamil hydrochloride | |
| HUE058725T2 (hu) | Eljárás aminok elõállítására | |
| AU2018297073A1 (en) | Process for the preparation of morphinane compounds | |
| HUP1800278A2 (en) | Process for the preparation of boc-linagliptin | |
| HUE053496T2 (hu) | Eljárás izocianátok elõállítására | |
| IL274560A (en) | A process for the preparation of raltagravir | |
| IL265013B (en) | Process for the preparation of 2-(6-nitropyridin-3-yl)-9h-dipyrido[3,2-b;3',4'-d]pyrrole | |
| IL268103A (en) | A process for the preparation of chiral pyrrolidine-2-yl-methanol derivatives | |
| HUP1800397A2 (en) | Process for the preparation of lumateperone and salts thereof |